

Anti-Procollagen type IIA N-terminal propeptide (human, PIIANP)**Mouse monoclonal antibody**Subclass: IgG₁/k

Clone: 2

CAT. NO.

BTE 003-02

SPECIFICITY BTE 003-02 is specific for human PIIANP.**IMMUNOGEN** Recombinant expressed PIIANP**TESTED APPLICATIONS** ELISA, IHC-P**SPECIES REACTIVITY (POSITIVE)** Human**SPECIES REACTIVITY (NEGATIVE)** Not determined**EPITOPE SPECIFICITY** Epitope is located at the amino-terminal part of procollagen type IIA

PRESENTATION**Content:** Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.**Preparation:** Protein-A purified**Form:** Liquid**Solvent:** 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide**Storage:** 4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION**ELISA:** BTE 003-02 also reacts with recombinant PIIANP coated directly onto the microtiter well.**IHC:** BTE 003-02 diluted in 10%FCS/TBS is well suited for immunohistochemistry on formalin-fixed, paraffin-embedded fetal tissue.**TARGET**

Collagen type II is the most abundant protein of cartilage matrix. Two isoforms exist and collagen type IIA is involved in early development of cartilage in embryos. The collagen is produced from type II procollagen when two teloterminal propeptides are digested from the precursor and released into the circulation. Procollagen type II N-terminal propeptide (PIIANP) is considered a marker of cartilage synthesis and the normal concentration in serum is approximately 30ng/mL.

REFERENCES**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.